The effect of a mobile application on treatment adherence and symptom management in patients using oral anticancer agents: A randomized controlled trial.


Karaaslan-Eşer A., AYAZ ALKAYA S.

European journal of oncology nursing : the official journal of European Oncology Nursing Society, vol.52, pp.101969, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 52
  • Publication Date: 2021
  • Doi Number: 10.1016/j.ejon.2021.101969
  • Title of Journal : European journal of oncology nursing : the official journal of European Oncology Nursing Society
  • Page Numbers: pp.101969
  • Keywords: Cancer, Mobile applications, Oral anticancer agents, Oral chemotherapy, Medication adherence, Nursing, MEDICATION ADHERENCE, CHEMOTHERAPY ADHERENCE, ASSESSMENT SCALE, TURKISH-VERSION, CANCER-PATIENTS, HEALTH-CARE, INTERVENTION, EDUCATION, WOMEN, APP

Abstract

© 2021 Elsevier LtdPurpose: The use of mobile health technologies in the management of oral anticancer agents (OAA) can be beneficial in terms of treatment adherence and symptom management. This study was conducted to investigate the effect of a mobile application developed for patients using OAA on treatment adherence and symptom management. Method: The study was conducted using a randomized controlled trial design, and it was carried out on 77 patients. Data were collected from the Oral Chemotherapy Adherence Scale (OCAS), and the Memorial Symptom Assessment Scale (MSAS). Data were collected at the beginning of the research, and face-to-face interviews were conducted after one, three, and six months. Patients in the intervention group were followed up for six months using the mobile application. Results: It was found that there was no difference between the intervention and control groups in the baseline OCAS mean scores (p > 0.05), and the mean score of the intervention group increased over the first, third- and sixth-month measurements (p < 0.05). It was found that there was no difference between the intervention and control groups in the MSAS mean scores (p > .05), and there was a decrease in the mean MSAS score of the intervention group between the third- and sixth-month follow-up (p < .05). Conclusion: The present study results showed that the mobile application is effective in managing symptoms and increasing treatment adherence. A well-designed mobile health application that increases treatment adherence, decreases symptom severity, and supports patients’ self-management could be beneficial for patients using OAA. ClinicalTrials.gov Identifier: NCT04626830